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ABSTRACT 
Mini-tablets represent a new trend in solid dosage form design, with the main goal of overcoming some therapeutic obstacles. Mini tablets 
are multiple unit dosage forms and are advantageous than pellets or any other oral dosage forms as they are easy to manufacture and 
stability problems are less. Offering some therapeutic benefits such as dose flexibility and combined release patterns. They do not require 
any solvent for their production and also local irritation can be avoided by the use of mini tablet Mini tablet offer several advantages like 
they can be manufactured relatively easily, They are not require less coating materials and also there is a great flexibility during their 
formulation development. Mini tablet are more acceptable in children and elderly people as they are easy to swallow. The objective of 
controlled drug delivery systems is to reduce the frequency of the dosing and to increase the effectiveness of the drug by localization. 
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INTRODUCTION 
Tablets are the most widely used solid dosage form and 
there is always scope for improving the limitations of 
tablets like, difficulty in swallowing and delay in the onset 
of Action 1. Mini- tablets are novel multiple unit solid 
dosage form which are in the size equal to or smaller than 
3.0mm in Diameter2. Over a decade now Fast-
disintegrating tablets (FDTs), have gained enormous 
popularity for better patient compliance and Acceptance 3. 
FDTs ease of administration without water and provide the 
fast onset of action is also the reason for their gaining 
popularity in the general Population4.. Also, FDTs have the 
proven potential in increasing the bioavailability of low 
aqueous soluble drug through fast disintegration and 
enhanced dissolution rate 5.Mini- tablets are novel multiple 
unit solid dosage form which are in the size equal to or 
smaller than 3.0mm in diameter6.Oral administration of 
medicines has an advantage for patient’s compliance. Most 
of the solid dosage forms administered orally is tablets. 
Tablets have many advantages over other dosage forms, 
such as ease of transportation, application and production, 
high patient compliance, accurate dosing, control of drug 
release and stability. However, the desired release proﬁle, 
therapeutic effect or ease of use in pediatrics or geriatrics, 
difficulty in swallowing may not be achieved by 
conventional tablets. Drug delivery system ensures 
reaching the effect area of the administered drug and 
sufficient concentration of the drug at the site of action. 
These factors, such as repetitive dosing, unpredictable 
absorption and undesirable toxicity lead to the 
development of controlled drug delivery system. The main 
aim in designing sustained or controlled drug delivery 
systems is to reduce the frequency of the dosing and to 
increase the effectiveness of the drug by localization at the 
specific site of action.  
Mini-tablets are tablets with a diameter ≤ 3 mm produced 
on conventional tablet presses equipped with multiple 
tooling. This production is similar to the production of 
standard tablets but requires excellent powder flow due to 
the small dies, exact control of process parameters and 
special caution during tablet press assembly in order to 
avoid tool damage. Mini-tablets (coated or uncoated and 
single or multiple-unit systems) are mainly developed as 
patient-friendly systems for pediatric and geriatric 
patients and also for personalized medicine because they 
offer improved swallowing and flexible dosing, combining 
various release kinetics, doses and active compounds in 
only one system. Mini-tablets may also be successfully 
used as multiple-unit modified release systems (extended 
release, delayed-colon release, pulsatile and bi-modal 
release and gastro retentive systems) providing improved 
drug bioavailability compared with single-unit systems. 
Oral controlled release drug delivery systems can be 
classified in two categories:  
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 Single unit dosage forms (SUDFs), like tablets or 
capsules, and  
 Multiple unit dosage forms (MUDFs), like granules, 
pellets or mini-tablets. 
 
Figure 1:  Mini tablets 
Mini tablet is with diameter of 3-6mm. Majority of the 
drugs absorption is more in upper part of small intestine 
(duodenum), for a drug to reach the small intestine it had 
to pass through stomach6. So, drug absorption depends on 
gastric empting time. If the gastric emptying is too fast 
drug may not absorb to required level or if it too slows it 
may get mix-up with gastric contents and may adsorb to 
food which gives unintended effects. These effects are 
more in case of single unit dosage forms because of their 
size but in case of mini tablets will not depend on gastric 
emptying and easily get passed through pylorus. So mini 
tablets are beneficial over the normal size tablets to reduce 
intra and inter subject variability. Mini tablets will give 
reproducible plasma drug concentrations. Plasma drug 
concentration is directly proportional to the absorption7. 
Absorption is more and even with mini tablets as they are 
distributed all over the surface which is not in case of 
single unit dosage forms. So by formulating multiple unit 
dosage forms like mini tablets better plasma drug profiles 
can be obtained. Mini tablets can be easily divided and 
administered without loss of activity. Elderly and 
pediatrics patients who sometimes chew the tablets which 
releases drug all at once and may cause toxicity in case of 
normal tablet but in case of Mini tablets, they can be 
chewed as here each mini depot in the formulation act 
individually dose dumping may not occur. For local 
irritating drugs, mini tablet formulation decreases the 
irritation effect than that of single unit formulations 7 
Constituents of Mini-Tablets 
Different mini-tablets can be formulated and designed 
individually, incorporated into a capsule to release the 
drug at different sites and at different rates. Different 
combinations of mini-tablets include immediate release, 
delayed release, and/or controlled release formulations. 
Also, combining different mini-tablets together, 
incompatible drugs can be administered. This, as a result, 
improves overall therapeutic outcome, and also concurrent 
diseases can be treated effectively8. 
Release profile 
Due to increased surface in relation to volume, the drug 
can be released more efficiently in case of mini-tablets. By 
applying uniform layer of a retarding film coat, the release 
rate of the drug can be controlled with greater certainty. 
Also, mini-tablets that are formulated using different 
concentrations of HPMC K100M, provides a prolonged 
drug release rates. The drug contained in the mini-tablets 
gets released at different rates, depending upon 
composition of mini tablets. Based on the release kinetic 
parameters calculated, it can be concluded that mini-
tablets containing HPMC K100M are particularly suitable 
to release the drug over hours of time periods9. 
By combining different doses of mini tablets, it is possible 
to achieve various releases with one formulation. Due to 
significant smaller dimensions of the mini tablets, when 
compared to normal tablets, they pass through the 
stomach at more even rate. As a result, the concentration of 
the drug in the blood can be easily reproduced. 
Advantages of Mini Tablets: 
 Mini Tablets can be manufactured relatively easily. 
 They offer high drug loading, a wide range of release 
rate designs, and fine tuning of these release rates10. 
 They have excellent size uniformity, regular shape and 
smooth surface. 
 They offer high degree of dispersion in the GI tract, 
thus minimizing the risks of high local drug 
concentrations. 
 They have less risk of dose dumping11. 
 They have less risk of dose dumping, less inter- and 
intra- subject variability, high degree of dispersion in 
the digestive tract thus minimizing the risks of high 
local drug concentrations. 
 They can be produced in a reproducible and 
continuous way. 
 They combine the advantages of MUDFs with the 
established manufacturing techniques in tableting and 
have fewer constraints compared to 
extrusion/spheronization technique12. 
 They offer high drug loading, a wide range of release 
rate patterns, and also fine tuning of these release 
rates. 
 Mini-tablets also offer an alternative for pellets 
because of their relative ease of manufacturing and 
because dosage forms of equal dimensions and weight 
with smooth regular surface are produced in a 
reproducible and continuous way. 
 They offer a substrate which is easy to coat with 
polymeric membranes for modified release purposes. 
 Mini tablets have less inter and intra- subject 
variability. 
 Mini tablets are easy to manufacture compared to 
pellets as they have equal dimensions, weight with 
smooth regular surface13.  
 Mini tablets are good coating substrates as they have 
excellent size uniformity, regular shape and a smooth 
surface. 
Unlike pellets, mini tablets do not require any solvents for 
its production; as a result problems with stability can be 
avoided9,10. 
Advantages of mini tablets over pellets 
  Mini tablets do not require any solvents for its 
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production; as a result problems with stability can be 
avoided14. 
 Pellets are small bead like structures, usually with 
medium to high uniformity and are usually filled into 
capsules (Figure 2) or compressed into tablets. 
 Technically demanding process like fluid bed 
granulation, extrusion or spheronization are required 
for the production of pellets. Whereas, mini tablets 
can be manufactured via simple tabletting 
procedures15. 
As mini-tablets have well designed size, shape, 
smooth surface, low degree of porosity and 
high mechanical strength, they are easy to coat 
than pellets, which usually have an uneven 
surface and are very porous. Hence, tablets 
with defined size, shape and surface can be 
easily produced with good batch to batch 
uniformity. 
Possibilities of Formulating Mini-Tablet Dosage 
Forms  
1. Compressed mini-tablets  
2. Encapsulated Coated mini-tablets   
3. Compressed mini-tablets presented as a 
biphasic drug delivery system   
Compressed mini tablet  
In order to avoid the cost of hard gelatin 
capsules, mini tablets can be formulated as 
tablet. Uniform sizes, smooth shapes, smooth 
surfaces, low porosity and high mechanical 
resistance make them more uniform and 
reproducible tablets than pellets and 
granules16. Depending on the properties of the 
external phase that provides the filling of the 
cavity (hydrophobic / hydrophilic polymer 
matrix used and the number of mini tablets), 
release profile can be changed. Biphasic drug 
delivery systems are developed using different 
release characteristics. In these systems, one 
phase initiates the rapid action by providing 
the immediate release while the other phase 
releases the long-term effect, ensuring 
continuity of efficacy and eliminating the need 
for recurrent doses of the drug 13, 14, 15. 
 
Figure 2: Compressed Mini-tablets 
Encapsulated coated mini-tablets systems   
Coated oral sustained-release forms of drugs are widely 
used to improve drug tolerance or to yield a dosing 
regimen that is easier to manage for patients. However, 
little published information is available on sustained-
release systems using coated mini-tablets17.  
In particular, it has proven challenging to develop one 
dosage form with sustained and immediate-release 
properties. A multifunctional and multiple unit system, 
which contains versatile mini-tablets in a hard gelatin or 
HPMC capsule, can be developed by preparing Rapid-
release Mini-Tablets (RMTs), Sustained-release Mini-
Tablets (SMTs), Pulsatile Mini Tablets (PMTs), and 
Delayed-onset Sustained-release Mini-Tablets (DSMTs), 
each with various lag times of release. Based on the 
combinations of mini-tablets, multiplied pulsatile drug 
delivery system (DDS), site-specific DDS, slow/quick DDS, 
quick/slow DDS, and zero order DDS could be obtained. 
Inclusion of RMTs permits the development of rapid-acting 
encapsulated dosage forms with optimal pharmacokinetic 
profiles for fast action. The size of the tablet can be 
reduced such that it could be enclosed in a capsule, then 
deploy tablets with different release properties within the 
one capsule. Several mini-tablets can be placed into each 
HPMC capsule, which later disintegrates and releases these 
subunits. Because several mini tablets can be placed into 
each capsule, tablets with different combination of drugs, 
dose and drug-release profiles can be included18.  
Compressed mini-tablets systems are presented 
as a biphasic delivery system: 
Biphasic delivery systems are designed to release a drug at 
two different rates or in two different periods of time: they 
are either quick/slow or slow/quick. A quick/slow release 
system provides an initial burst of drug release followed by 
a constant rate (ideally) of release over a defined period of 
time and in slow/quick release system provides release 
vice versa. Biphasic release system is used primarily when 
maximum relief needs to be achieved quickly, and it is 
followed by a sustained release phase to avoid repeated 
administration. Suitable candidate drugs for this type of 
administration include non-steroidal anti-inflammatory 
drugs (NSAIDs) antihypertensive, antihistaminic, and anti-
allergic agents19. Generally, conventional controlled dosage 
forms delay the release of therapeutic systemic levels and 
do not provide a rapid onset of action. While immediate 
release granules give fast release to provide rapid onset of 
action, but fails to provide longer duration of action. A 
relatively constant plasma level of a drug is often preferred 
to maintain the drug concentration within the therapeutic 
window. However, it is difficult to achieve, especially for 
once-daily dosage forms, partly because the environment 
for drug diffusion and/or absorption varies along the 
gastrointestinal (GI) tract. On the basis of these 
considerations, we have proposed a new oral delivery 
device, in the form of a double-component tablet and 
granules, in which the one portion is formulated to obtain a 
prompt release of the drug, with the aim of reaching a high 
serum concentration in a short period of time. The second 
portion is a sustain release matrix, which is designed to 
maintain an effective plasma level for a prolonged period 
of time20. This concept can be used to produce a biphasic 
delivery system combining a fast release together with the 
slow release period of the drug, provided that the 
excipients powder that fills The void spaces between the 
mini-tablets incorporate a part of the total drug dose. This 
system can produce a rapid rise in the plasmatic 
concentrations for some drugs (such as analgesic, anti-
inflammatory, anti hypertensive and antihistaminic 
agents) that are requested to promptly exercise the 
therapeutic effect, followed by an extended release phase 
in order to avoid repeated administrations17. 
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Types of Mini tablets 
Enteric coating is a barrier applied to oral medication that 
controls the location in the digestive system where it is 
absorbed. Most enteric coatings work by presenting a 
surface that is stable at the highly acidic pH found in the 
stomach, but breaks down rapidly at a less acidic 
(relatively more basic) pH. For example, they will not 
dissolve in the acidic juices of the stomach (pH ~3), but 
they will in the alkaline (pH 7-9) environment present in 
the small intestine. Materials used for enteric coatings 
include fatty acids, waxes, shellac, plastics, and plant fibres. 
Drugs that have an irritant effect on the stomach, such as 
aspirin, can be coated with a substance that will dissolve 
only in the small intestine. Likewise, certain groups of 
azoles (esomeprazole, omeprazole, pan and all grouped 
azoles) are acid-activated. For such types of drugs, enteric 
coating added to the formulation tends to avoid activation 
in the mouth and oesophagus. Recently, some companies 
have begun to utilize enteric coatings on fish oil (omega-3 
fatty acids) supplements. The coating prevents the fish oil 
capsules from being digested in the stomach, which has 
been known to cause a fishy reflux (fish burps). Sometimes 
the abbreviation "EC" is added beside the name of the drug 
to indicate that it has an enteric coating21.    
Mini tablets can be classified based on the target site, 
method of manufacturing, patient needs as follows: 
1. Pediatric mini tablets 
2. Oral disintegrating mini tablets 
3. Gastro retentive min tablets 
4. Bio-adhesive mini tablets 
5. Biphasic mini tablets 20, 21.  
Pediatric mini tablets 
Syrups, tablets and capsules are commonly used dosage 
forms for children. Syrups are liquid dosage forms which 
are simple to administer and dose can be easily altered to 
the patient needs on the other side disadvantages with 
these liquids dosage forms are chemical, physical, and 
microbial instability, taste issues, lack of controlled release 
and formulation problems. In case of tablets as they are big 
in size difficulty in swallowing and dose adjustment is 
difficult. Some time we have to break the tablets and 
administer which causes loss of activity of the tablets. 
Patient compliance is another issue with the conventional 
dosage forms. To overcome all the above issues 
formulating mini tablets can result in good patient 
acceptance. Mini tablets are easily accepted by children 
than other dosage forms like tablets, syrups, and capsules 
etc22. 
pH responsive mini tablets 
The pH of human Gastro Intestinal Tract varies greatly 
(Stomach 1.5-3.0, upper part of small intestine Duodenum 
4.0-5.0, lower parts of SI jejunum and ileum 6.5-7.5, and 
colon 5.6-6.9). pH responsive drug release is required 
when absorption of drug is more at a particular site this 
can be achieved by coating with pH responsive release 
polymers like Eudragits. Generally coating is done to 
granules and then they are filled into capsules to achieve 
the required release at required tablets can be used as an 
alternative to pellets. M A Hadi et al. formulated pH 
responsive mini tablets for ileo colonic drug delivery of 
naproxen which is used for the treatment of rheumatoid 
arthritis. Eudragit L100 and Eudragit S100 are used as pH 
responsive polymers to get the required release23. 
Oral disintegrating mini tablets 
Oral dispersible tablets (ODTs) are the novel dosage form 
which rapidly disintegrates in the mouth (1-3 min) without 
chewing upon oral administration and without the need of 
water, unlike other conventional oral solid dosage form. 
Oral Dispersible Tablets (ODTs) are also known as “fast 
dissolve”, “rapidly disintegrating”, “quick-dissolve”, 
“crunch-melt”, “bite-dispersible”, “mouth-dissolve”, and 
“orodispersible” tablets . Oral dispersible mini tablets 
(ODMTs) are more suitable for paediatric patients because 
of their small size, pleasant mouth feel and fast 
disintegration in mouth. The ODT should have the 
following characters they should disintegrate in the mouth 
without additional water. The disintegrated tablet should 
become a soft paste or liquid suspension, which can 
provide good mouth feel and smooth swallowing. Because 
ODTs dissolve or disintegrate in the patient’s mouth, the 
drug will be partially dissolved in close proximity to the 
taste buds. A pleasant taste inside the mouth becomes 
critical for patient acceptance. Unless the drug is tasteless 
or does not have an undesirable taste, taste-masking 
techniques should be used. The taste-masking technology 
should also be compatible with ODT formulations22. 
Gastro retentive mini tablets or Floating mini 
tablets 
Gastro retentive mini tablets are intended to release the 
drug in stomach for prolonged time. Generally for tablets 
to float on the GI fluids content we formulate tablets by 
using gas generating agents in them. These tablets when 
come in contact with food generate CO2and the generated 
gas is trapped in swellable hydrocolloid which makes the 
tablet to float and retain in stomach. In normal single unit 
tablets drug loading is low as the polymer used for floating 
in high. In mini tablets we can use coating with sodium 
bicarbonate or calcium carbonate (gas generating agents), 
eudragits coating in place of swellable polymers used in 
formulation to increase the drug loading. Fluid bed 
processor can be used for coating of mini tablets. Goole et 
al developed sustained release floating mini tablets of 
levodopa. Here they used 3mm mini tablets core 
formulated with gas generating agent and coated the core 
with eduragit RL30 D to get the required release 23. 
Bioadhesive Vaginal Mini Tablets 
The various available dosage forms for vaginal drug 
delivery are creams, gels, ointments and tablets. The 
problems with these are leakage, messy, less patient 
compliance and less retention time. Nano pharmaceuticals 
can be used but the problem associated with them is low 
residence time as they are liquid in nature. To overcome 
the above problems we can use bio adhesive polymers. Bio 
adhesive polymers or hydrophilic polymers are readily 
soluble and adhesive on exposure to moisture and will 
rapidly cohere to surfaces as they have high viscosity at 
low concentrations. Solid dosage forms have high dose 
accuracy than semisolids systems. The problem in solid 
dosage forms is vaginal disintegration is slow and they are 
rapidly cleared due to gravity and self-cleansing action of 
vagina. Bio adhesive polymers can be used to overcome 
this but in large size tablets loss is reported5. 
Bio adhesive mini tablets can be used for vaginal drug 
delivery to deliver drug accurately and for long period of 
time. In mini tablets dose is divided into multiple units 
which will spread evenly in vaginal cavity with improved 
coverage in vaginal epithelium. Bio adhesive Mini tablets 
act by swelling and forming micro gels and releasing drug 
in controlled release manner and there by maximum 
bioavailability can be achieved. 
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Marianne Hiorth et al were Prepared Bioadhesive mini 
tablets of hexyl ammonium hydro chlorodium (HAL), 
which are used for the photodynamic therapy of cervical 
cancer. Thermo gel of HAL is already there but HAL is 
unstable in moist environment, to prevent or to eliminate t 
he stability issues bio adhesive mini tablets were prepared 
by direct compression7. Mini tablets prepared with HPMC 
and HPC have shown adequate mechanical and bio 
adhesive properties. Vaginal pH varies from women to 
women of different ages. To withstand those pHconditions 
bio adhesive vaginal mini tablets are to be designed by 
using non-ionic cellulose ethers with Bioadhesive property 
24. 
Methods of manufacturing mini tablets: 
Some of the methods that can be used for the 
manufacturing of mini tablets are 
1. Direct compression 
2. Wet granulation 
3. Dry granulation 
4. Melt- extrusion 
Direct compression technique 
Direct compression is the process by which tablets are 
compressed directly from powder blends containing API 
and excipients directly compressed the powder blend into 
biconvex mini tablet. Excipients of direct compression 
grade are used here to get the required hardness. Stability 
problems are less compared to that of tablets prepared by 
wet granulation21. 
Wet granulation 
Wet granulation involves the use of binder solution to form 
granules which then compressed in compression machine 
to get mini tablets. Polyvinyl pyrrolidone of different 
grades is generally used as a binding agent. 
Dry granulation technique 
Dry granulation is rational technique of choice for the 
manufacture of tablets containing thermo labile and 
moisture-sensitive drugs. This technique employs 
processing equipment known as roller compactor or 
chilsonator. This machine compress as premixed powders 
between two counter rotating rollers under extreme 
pressure. The resultant material is in the form of a brittle 
ribbon, sheet, or piece-depending on the configuration of 
the roller. The compressed material is reduced to the 
proper size to form granules that are mixed with other in-
active excipients and finally compressed on a rotary 
compression machine15. 
Melt-Extrusion technique 
In melt-extrusion technique, the powder (API+ excipients) 
were premixed this premixed powder is then transferred 
to melt-extruder. In melt-extruder parameters like screw 
speed, feed rate and temperature are set in the range of 
melting point range of material. After the process the 
extrudates are then milled and sieved. The obtained 
granules are then compressed to mini tablets using 
compression machine 25. 
Encapsulated mini-tablets system usually comprises 
immediate-release mini-tablets (IRMT) and sustained 
release mini-tablets (SRMT) in a capsule made from HPMC, 
a water-soluble polymer. HPMC capsule which contains the 
mini-tablets later disintegrates and releases these subunits 
into the system. As several mini-tablets can be placed in 
each capsule, tablets with different dose, content and 
release characteristics can be included18. 
Inclusion of IRMT permits the development of rapid acting 
dosage forms for fast action. Encapsulated minitablets 
systems can be designed to yield various sustained release 
drug profiles by combining different types, quantities and 
combinations of mini-tablets, thereby improving patient 
compliance. 
Mini-tablets are usually coated with enteric coating 
polymers in fluid bed coater or in modified coating pans17. 
Enteric coating is a polymer barrier, which when applied to 
a drug protects it from the acidic pH of the stomach, and 
releases the drug in the alkaline environment of the small 
intestine. That is, they will not get dissolved in the acidic 
juices of the stomach, but breaks down in the alkaline 
environment of the small intestine. Materials used for 
enteric coatings mostly include fatty acids, waxes, 
phthalates, shellac, plastics, and plant fibres21. 
Drugs that cause irritation to gastric mucosa or inactivated 
in the stomach, can be coated with a substance that will 
dissolve only in the small intestine. Abbreviation "EC" 
along with the name of the drugindicates that the drug has 
an enteric coating 26. 
Formulation of mini-tablet-in-capsule systems 
The formulation process of mini-tablet-in-capsule systems 
canbe divided into three important steps: 
 The formulation/production of mini-tablets, 
 Coating of these mini-tablets with appropriate coating 
polymer, Filling of coated mini-tablets into hard 
gelatin or HPMC capsules (Mini-tablets-in-capsule 
systems)17. 
Preparation of mini-tablets-in capsule system and 
granules-mini-tablets-in-capsule systems: Formula 
used for the calculation of immediate-release dose 
The pharmacokinetic parameters of drug were utilized for 
the calculation of theoretical drug release profile for coated 
mini-tablet-in-capsule system. The immediate-release part 
of drug was calculated using the following equation. 
 DL = CmaxVd  
Where Cmax is maximum plasma concentration, and Vd is 
volume of distribution. 
Preparation of immediate release component 
(Granules) 
Calculated amount of immediate-release dose drug and 
other suitable excipients [Microcrystalline cellulose (Avicel 
PH 102)] were used because of its good compaction and 
disintegration properties. Any suitable superdisintegrants 
was used to obtain an immediate release of the drug. The 
granules were prepared by wet granulation method22. 
Preparation of immediate-release coated mini-tablet 
(IRCMT) 
The IRCMT was prepared using the wet granulation 
method. 
Preparation of sustained-release coated mini-tablet 
(SRCMT) 
The SRCMT was prepared using the same method as used 
for preparing the IRCMT. However, the SRCMT did not 
contain the any superdisintegrants. A coating suspension 
was prepared from HPMC (5cps/15cps), ethyl cellulose, 
magnesium stearates, ethyl alcohol and water. Magnesium 
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stearate was used in the coating preparation to minimize 
friction between the surfaces of mini- tablets, the mini-
tablets-filling system and the HPMC capsules18. 
Preparation of coated mini-tablet-in-capsule system 
To prepare the CMTICS, two IRCMT and three SRCMT were 
placed in each HPMC capsule (size1). Both 
similar/different ratios of SRCMT were placed in each 
HPMC capsule to achieve various sustained release profiles 
of the CMTICS 27,28. 
Mini tablets can be administered by following methods 
 Directly administered as single units. 
 Filled in hard gelatine capsules. 
 Use of automatic Dose dispensing device29. 
Directly administered as single units 
Mini tablets can be directly administered as such. Required 
dose can be easily taken and these are packed in bottles. 
Sometime compressed mini tablets are again compressed 
to get tablets of normal size. 
Filled in hard gelatin capsules 
As it is difficult to handle the mini tablets these are usually 
filled in hard gelatin capsules and then administered30. 
Automatic dose dispensing device 
Dose is decided on the basis of patient population average 
dose individualization is important as administration of 
right drug in wrong dose will result in adverse effects of 
decreased efficiency. Generally tablets are most commonly 
used but limited strengths available for administration. 
Dividing tablets for getting required dose or combining 
different strengths will not give the desired therapeutic 
effect so an automatic dose dispensing device can used to 
dispense tablets of required dose31. 
Disintegration test 
a. Hard gelatin capsules: Disintegration time shall not be 
more than 30 min. 
b. Soft gelatin capsules: Disintegration time shall not be 
more than 60 min. 
c. Enteric capsule: In Acidic media; shall not 
disintegration 2 hrs and in alkaline medium capsules 
shall disintegrate within 30 min28. 
F) In-vitro drug release 
 Mini-tablets were subjected to in-vitro drug release 
studies in simulated gastric and intestinal fluids to   
assess their ability in providing the desired controlled 
drug delivery 29. 
 Drug release studies3,54, 55 were carried out using 
USP dissolution test apparatus I at 100 rpm, 37±0.5°C, 
and pH 1.2 buffer (900 ml) (i.e. 0.1 N HCl) for 2 hours, 
since the average gastric emptying time is about 2 
hours. The dissolution medium was replaced with pH 
6.8 phosphate buffer (900ml) and experiment 
continued for another 10 hours. At different time 
intervals, 5ml of the samples were withdrawn and 
replaced with 5ml of drug-free dissolution 
medium30.  
 The samples withdrawn were analyzed by UV 
spectrophotometer using multi component mode of 
analysis at required wave length. 
Preformulation studies mini-tablets 
Preformulation study relates to pharmaceutical and 
analytical investigation carried out proceeding and 
supporting formulation development efforts of the dosage 
form of the drug substance. It gives information needed to 
define the nature of the drug substance and provide frame 
work for the drug combination with pharmaceutical 
excipients in the dosage form. Hence, the following 
preformulation studies were performed on the obtained 
sample of drug17. 
1. Angle of repose 
2. Bulk density and Tapped density 
3. Carr’s index 
4. Hauser’s ratio 
1. Angle of repose 
The angle of repose is determined by fixed funnel and free 
standing cone methods employ a funnel that is secured 
with its tip at a given height, h, which was kept 2 cm above 
graph paper that is placed on a flat horizontal surface15. 
2. Bulk density and tapped bulk density 
Bulk density and tapped bulk density was determined. A 
quantity of 2gm of granules from each formula, previously 
light Shaken for the break of any agglomerates formed, was 
introduced into the 10 ml of measuring cylinder. After the 
initial volume was observed, the cylinder was allowed to 
fall down its own weight from the hard surface from a 
height of 2.5cm at 2 sec Intervals. The tapping was 
continued until no further change in the volume was noted 
LBD and TBD were calculated using the following 
formulas: LBD: Weight of the powder/volume of the 
packing.13 TBD: Weight of the powder/Tapped volume of 
the packing15. 
3. Compressibility index 
The compressibility index of the granules was determined 
by Carr’s Compressibility index. Carr’s index (%) = [(TBD-
LBD) * 100] / TBD 
Where, LBD: Weight of the powder/volume of the packing. 
TBD: Weight of the powder/Tapped volume of the packing 
[30].   
4. Hausner’s ratio 
Hausner’s ratio can be determined by the following 
equation, Hausner’s ratio = TBD / LBD Where, TBD -
Tapped bulk densities & LBD- Loose bulk densities31. 
1. <1.25 – Good flow = 20% Carr 
2. 1.25 – Poor flow =33% Carr’s 
3. Even Hausner's ratio indicates the flow properties of 
the powder blend and is measured by the ratio of 
tapped density to bulk density. 
Hausner’s ratio=Tapped density/Bulk density 
Drug excipients Compatibility study 
1. Compatibility of the drug with excipients was 
determined by FT-IR spectral analysis DSC thermal 
analysis, this study was carried out to detect any 
changes on chemical constitution of the drug after 
combined it with the excipients. The samples were 
taken for FT-IR and DSC studies31. 
a) FTIR studies 
IR spectra for pure drug and best mini-tablets formulations 
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were recorded in a Fourier transform infrared (FTIR) 
spectrophotometer (Shimadzu Corporation 8600, Japan) 
with KBr pellets32. 
b) DSC studies 
DSC studies were carried out for pure drug and best mini-
tablets formulations. DSC scan of about 5mg accurately 
weighed montelukast and optimized formulations were 
performed by using an automatic thermal analyzer system 
(DSC60 Shimadzu Corporation, Japan). Sealed and 
perforated aluminium pans were used in the experiments 
for all the samples. Temperature calibrations were 
performed using indium as standard. An empty pan sealed 
in the same way as for the sample was used as a reference. 
The entire samples were run at a scanning rate of 10° 
C/min from 50-300° C32. 
EVALUATION OF MINI-TABLETS 
Weight Variation Test   
For this test, 20 tablets are selected randomly from the 
batch and the individual weight of each tablet is noted. 
From this, the average weight is calculated. According to 
USP, none of the individual tablet weight should be less 
than 90% and more than 110% of the average weight. The 
specification of weight variation is 10%33. 
Hardness 
The hardness of the Mini tablet is determined using Pfizer 
hardness tester and expressed in kg/cm2. Six tablets were 
randomly picked from each formulation and the mean and 
standard deviation values were calculated.33-37 . 
Thickness 
Thickness of the Mini tablet is measured using a digital 
calipers and screw gauge. It is expressed in terms of mm38. 
Friability (F) 
Friability test of Mini tablets is conducted using Roche 
friabilator. For this, usually 20 mini- tablets are selected 
randomly from each batch and their initial weight (W0) is 
noted. The mini-tablets were initially weighed and 
transferred into friabilator. The drum was rotated at 25 
rpm for 4 minutes after which the mini-tablets were 
removed. Any loose dust was removed from the mini-
tablets as before and the tablets were weighed again 
(Wfinal)39.  
Drug content uniformity 
Five mini-tablets weighted and crushed in a mortar then 
weighed powder contained equivalent to 10 mg of drug 
transferred in 100 ml of dissolution medium to give a 
concentration of 100 μg/ml. Take 15 ml of this solution 
and diluted it up to 100 ml with same solution to give a 
concentration of 15μg/ml. Absorbance measured at 
respective wave length using UV-Visible spectro-
photometer40 . 
  
Table 1:   List of mini tablets Available in the market 
Generic Name  Brand Name 
Donepezil Hydrochloride Aricept 
Levonorgestrel and Ethinyl Estradiol Alesse 
Sumatriptan and Naproxen Sodium Tablets  Treximet 
Pancrelipase Ultresa 
Zafirlukast Accolate 
Galantamine HBr ER Razadyne ER 
Hydromorphone Hydrochloride Extended Release Tablets Exalgo 
Warfarin Sodium Coumadin 
Fenofibric Acid Capsules Trilipix 
Vorapaxar Tablets Zontivity 
Prasugrel Tablets Effient 
Olanzapine  Zyprexa, Zyprexa Zydis 
 
In-vitro drug release   
 Mini-tablets were subjected to in-vitro drug release 
studies in simulated gastric and intestinal fluids to assess 
their ability in providing the desired controlled drug 
delivery35. Drug release studies3,54, 55 were carried out 
using USP dissolution test apparatus I at 100 rpm, 
37±0.5°C, and pH 1.2 buffer (900 ml) (i.e. 0.1 N HCl) for 2 
hours, since the average gastric emptying time is about 2 
hours. The dissolution medium was replaced with pH 6.8 
phosphate buffer (900ml) and experiment continued for 
another 10 hours36 .At different time intervals, 5ml of the 
samples were withdrawn and replaced with 5ml of drug-
free dissolution medium. The samples withdrawn were 
analyzed by UV spectrophotometer using multi component 
mode of analysis at required wave length37. .In vitro drug 
release studies are carried out in USP type II dissolution 
test apparatus at specific rpm and temperature for definite 
time period in suitable buffer solution. All these factors 
depend on that particular formulation. From this, 10 ml of 
sample is withdrawn and analyzed using UV 
spectrophotometer at appropriate wavelength. After this, 
drug release is tested for definite time period, at same 
temperature and same rotational speed. At all the time 
points (15, 30, 60, 90, 120,240 and 360 minutes), 10 ml of 
the sample is withdrawn, and analyzed using UV- 
Spectrophotometer41. 
CONCLUSION 
From this review It can be easily concluded that 
Pharmaceutical mini tablet offer several advantages. Mini 
Tablets offer great advantage over single unit dosage 
forms. Accurate dose of drug can be given to patients to 
increase the efficiency. Compared to single unit dosage 
forms, mini tablets are good alternative to granules and 
pellets. However, production parameters must be carefully 
assessed to ensure a good ﬂow, correct and complete filling 
of the die and damage to the equipment. Dose dumping and 
local irritation can be avoided by the use of mini tablets. 
For those drugs whose absorption is more in small 
intestine mini tablet dosage form is beneficial as they can 
easily pass through the duodenum independent of gastric 
emptying and intestinal motility .Bio adhesive mini tablets 
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show increased bio adhesion and increased effect than that 
of single unit bio adhesive tablets. They are suitable for 
geriatric and pediatric patient groups compare to single 
unit dose forms and also good substitutes for granules and 
pellets.
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